A new standard of care for patients with surgically unresectable stage III non-small cell lung cancer

被引：1
|
作者：
Gill, Harpaul S. [1 ]
Ramalingam, Suresh S. [1 ]
机构：
[1] Emory Univ, Sch Med, Dept Hematol & Oncol, Winship Canc Inst, 1365 Clifton Rd NE,Bldg C,Suite 4014, Atlanta, GA 30322 USA
来源：
CANCER | 2019年 / 125卷 / 13期
关键词：
durvalumab; immune checkpoint inhibition; NSCLC; PACIFIC trial; stage III NSCLC; RANDOMIZED PHASE-III; RADIATION-THERAPY; CONCURRENT CHEMORADIOTHERAPY; SEQUENTIAL CHEMORADIOTHERAPY; CONSOLIDATION DOCETAXEL; THORACIC RADIOTHERAPY; TRIAL; CHEMOTHERAPY; COMBINATION; CARBOPLATIN;
D O I：
10.1002/cncr.31996
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Overall survival data from the PACIFIC trial have reaffirmed earlier US Food and Drug Administration approval of durvalumab in patients with stage III non-small cell lung cancer. In the current commentary, the authors provide a brief historical perspective on stage III disease as well as a further analysis of the strengths and weaknesses of the trial.
引用
收藏
页码：2148 / 2153
页数：6
相关论文
共 50 条
  • [21] Comparison of carboplatin and paclitaxel with or without bevacizumab in chemotherapeutic regimens for unresectable stage III non-small cell lung cancer
    Ding, T.
    Li, Z. -T.
    Zhang, X.
    Shi, Y. -T.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2017, 21 (16) : 3723 - 3729
  • [22] Induction treatment in patients with stage III non-small cell lung cancer
    Palmero, Ramon
    Vilarino, Noelia
    Navarro-Martin, Arturo
    Nadal, Ernest
    TRANSLATIONAL LUNG CANCER RESEARCH, 2021, 10 (01) : 539 - 554
  • [23] Is durvalumab the solution for unresectable stage III non-small cell lung cancer?
    Duma, Narjust
    Mansfield, Aaron S.
    TRANSLATIONAL CANCER RESEARCH, 2018, 7 : S89 - S93
  • [24] A Glimpse Into the Future for Unresectable Stage III Non-Small Cell Lung Cancer
    Bartolomeo, Valentina
    Cortiula, Francesco
    Hendriks, Lizza E. L.
    De Ruysscher, Dirk
    Filippi, Andrea R.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 118 (05): : 1455 - 1460
  • [25] PACIFIC: An Ocean of Hope in Patients With Stage III Unresectable Non-Small Cell Lung Cancer
    Uprety, Dipesh
    Marinier, David E.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2018, 16 (05): : 458 - 460
  • [26] Ineligibility for the PACIFIC trial in unresectable stage III non-small cell lung cancer patients
    Kazutaka Hosoya
    Daichi Fujimoto
    Hayato Kawachi
    Yuki Sato
    Mariko Kogo
    Kazuma Nagata
    Atsushi Nakagawa
    Ryo Tachikawa
    Shinya Hiraoka
    Masaki Kokubo
    Keisuke Tomii
    Cancer Chemotherapy and Pharmacology, 2019, 84 : 275 - 280
  • [27] Chemoradiation treatment patterns among United States Veteran Health Administration patients with unresectable stage III non-small cell lung cancer
    Hung, Anna
    Lee, Kyung Min
    Lynch, Julie A.
    Li, Yanhong
    Poonnen, Pradeep
    Efimova, Olga V.
    Hintze, Bradley J.
    Buckingham, Trudy
    Yong, Candice
    Seal, Brian
    Kelley, Michael J.
    Reed, Shelby D.
    BMC CANCER, 2021, 21 (01)
  • [28] Treatment of unresectable stage III non-small cell lung cancer for patients who are under-represented in clinical trials
    Bortolot, Martina
    Cortiula, Francesco
    Fasola, Gianpiero
    De Ruysscher, Dirk
    Naidoo, Jarushka
    Hendriks, Lizza E. L.
    CANCER TREATMENT REVIEWS, 2024, 129
  • [29] Persisting Gaps in Optimal Care of Stage III Non-small Cell Lung Cancer: An Australian Patterns of Care Analysis
    Woodford, Katrina
    Koo, Kendrick
    Reynolds, John
    Stirling, Robert G.
    Harden, Susan, V
    Brand, Margaret
    Senthi, Sashendra
    ONCOLOGIST, 2023, 28 (02) : E92 - E102
  • [30] Concurrent sintilimab with sequential chemoradiotherapy for unresectable, stage III non-small cell lung cancer: a retrospective study
    Tang, Shi
    Cong, Xiaofeng
    Zheng, Dan
    Chen, Chen
    Liu, Zengguang
    Gao, Jie
    Zhang, Huimin
    Zhang, Youhao
    Liu, Ziling
    FRONTIERS IN ONCOLOGY, 2023, 13
12345